Loading...

Enanta Pharmaceuticals

DB:9EP
Snowflake Description

Excellent balance sheet with solid track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
9EP
DB
$2B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. The last earnings update was 69 days ago. More info.


Add to Portfolio Compare Print
9EP Share Price and Events
7 Day Returns
-7.8%
DB:9EP
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
6.5%
DB:9EP
-9.2%
DE Biotechs
-6.7%
DE Market
9EP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Enanta Pharmaceuticals (9EP) -7.8% -18.4% 12.5% 6.5% 161.1% 180.3%
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • 9EP outperformed the Biotechs industry which returned -9.2% over the past year.
  • 9EP outperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
9EP
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Enanta Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Enanta Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €74.26.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Enanta Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Enanta Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:9EP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $4.46
NasdaqGS:ENTA Share Price ** NasdaqGS (2019-04-18) in USD $85.8
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Enanta Pharmaceuticals.

DB:9EP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ENTA Share Price ÷ EPS (both in USD)

= 85.8 ÷ 4.46

19.22x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Enanta Pharmaceuticals is good value based on earnings compared to the Europe Biotechs industry average.
  • Enanta Pharmaceuticals is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does Enanta Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:9EP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 19.22x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
-54.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

DB:9EP PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 19.22x ÷ -54.1%

-0.36x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Enanta Pharmaceuticals earnings are not expected to grow next year, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Enanta Pharmaceuticals's assets?
Raw Data
DB:9EP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $21.96
NasdaqGS:ENTA Share Price * NasdaqGS (2019-04-18) in USD $85.8
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:9EP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ENTA Share Price ÷ Book Value per Share (both in USD)

= 85.8 ÷ 21.96

3.91x

* Primary Listing of Enanta Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Enanta Pharmaceuticals is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Enanta Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Enanta Pharmaceuticals has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Enanta Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-54.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Enanta Pharmaceuticals expected to grow at an attractive rate?
  • Enanta Pharmaceuticals's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Enanta Pharmaceuticals's earnings are expected to decrease over the next 1-3 years, this is below the Germany market average.
  • Enanta Pharmaceuticals's revenues are expected to decrease over the next 1-3 years, this is below the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:9EP Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:9EP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts -54.1%
DB:9EP Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts -7.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:9EP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:9EP Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-09-30 175 -62 4
2022-09-30 155 -77 4
2021-09-30 167 -50 -67 5
2020-09-30 193 4 -21 6
2019-09-30 220 58 34 6
DB:9EP Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 238 55 86
2018-09-30 207 29 72
2018-06-30 215 58 81
2018-03-31 166 49 52
2017-12-31 131 54 34
2017-09-30 103 53 18
2017-06-30 40 -7 -21
2017-03-31 46 -4 -13
2016-12-31 50 9 -10
2016-09-30 88 36 22
2016-06-30 90 36 29
2016-03-31 87 23 33

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Enanta Pharmaceuticals's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • Enanta Pharmaceuticals's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:9EP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Enanta Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:9EP Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-09-30 -2.88 -1.42 -4.34 2.00
2022-09-30 -3.31 -2.39 -5.10 3.00
2021-09-30 -3.05 -2.77 -3.33 4.00
2020-09-30 -1.13 -0.53 -1.67 5.00
2019-09-30 1.76 2.13 1.35 4.00
DB:9EP Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 4.46
2018-09-30 3.74
2018-06-30 4.22
2018-03-31 2.74
2017-12-31 1.80
2017-09-30 0.93
2017-06-30 -1.08
2017-03-31 -0.70
2016-12-31 -0.50
2016-09-30 1.14
2016-06-30 1.55
2016-03-31 1.75

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Enanta Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Enanta Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Enanta Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Enanta Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Enanta Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Enanta Pharmaceuticals's year on year earnings growth rate has been positive over the past 5 years.
  • Enanta Pharmaceuticals's 1-year earnings growth exceeds its 5-year average (150.9% vs 8.9%)
  • Enanta Pharmaceuticals's earnings growth has exceeded the Europe Biotechs industry average in the past year (150.9% vs 18.2%).
Earnings and Revenue History
Enanta Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Enanta Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:9EP Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 238.40 86.27 24.82 111.77
2018-09-30 206.63 71.96 23.44 94.86
2018-06-30 215.35 81.04 22.73 84.45
2018-03-31 165.60 52.33 21.83 71.37
2017-12-31 130.51 34.38 21.58 62.89
2017-09-30 102.81 17.71 20.75 57.45
2017-06-30 39.73 -20.60 20.07 52.44
2017-03-31 46.20 -13.25 19.12 47.82
2016-12-31 50.24 -9.50 18.09 43.95
2016-09-30 88.27 21.67 16.97 40.46
2016-06-30 89.84 29.28 16.22 36.01
2016-03-31 87.46 32.77 15.58 31.48
2015-12-31 131.83 63.17 14.59 27.70
2015-09-30 160.88 78.99 13.54 23.19
2015-06-30 149.10 68.14 12.61 21.34
2015-03-31 179.55 115.77 11.57 19.64
2014-12-31 124.35 81.82 10.70 19.00
2014-09-30 47.74 34.44 10.02 18.74
2014-06-30 46.45 35.04 9.01 17.84
2014-03-31 6.05 -19.15 8.19 17.32
2013-12-31 5.09 -18.94 7.12 16.31
2013-09-30 32.05 -6.57 6.18 16.84
2013-06-30 32.56 -2.57 6.13 16.80
2013-03-31 33.46 -3.26 5.49 17.68
2012-12-31 68.82 8.83 5.20 17.24
2012-09-30 41.71 1.37 5.30 15.12
2012-06-30 39.85 1.30 4.81 13.79

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Enanta Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Enanta Pharmaceuticals used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Enanta Pharmaceuticals's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Enanta Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Enanta Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Enanta Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Enanta Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Enanta Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Enanta Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Enanta Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 222.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Enanta Pharmaceuticals Company Filings, last reported 3 months ago.

DB:9EP Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 426.84 1.90 345.79
2018-09-30 393.68 1.92 308.73
2018-06-30 360.90 1.84 273.23
2018-03-31 333.40 1.87 256.72
2017-12-31 317.58 1.89 220.44
2017-09-30 302.48 1.14 223.67
2017-06-30 262.16 0.64 192.02
2017-03-31 267.29 0.66 175.57
2016-12-31 269.43 0.68 209.36
2016-09-30 271.19 0.69 210.08
2016-06-30 270.24 0.71 218.47
2016-03-31 267.64 0.72 220.42
2015-12-31 265.57 0.75 180.02
2015-09-30 237.43 0.76 145.21
2015-06-30 229.74 0.36 154.29
2015-03-31 225.66 0.19 165.47
2014-12-31 195.14 0.18 104.02
2014-09-30 150.24 0.20 90.76
2014-06-30 154.63 0.21 95.89
2014-03-31 103.54 0.00 94.77
2013-12-31 107.22 0.00 91.90
2013-09-30 112.09 0.00 101.48
2013-06-30 116.20 0.00 94.55
2013-03-31 120.14 0.00 109.11
2012-12-31 68.20 0.00 45.49
2012-09-30 45.93 0.00 43.76
2012-06-30 49.70 0.00 46.76
  • Enanta Pharmaceuticals's level of debt (0.4%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 0.4% today).
  • Debt is well covered by operating cash flow (2899.7%, greater than 20% of total debt).
  • Enanta Pharmaceuticals earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess Enanta Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Enanta Pharmaceuticals has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Enanta Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Enanta Pharmaceuticals dividends.
If you bought €2,000 of Enanta Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Enanta Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Enanta Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:9EP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:9EP Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-09-30
2022-09-30
2021-09-30
2020-09-30
2019-09-30

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Enanta Pharmaceuticals has not reported any payouts.
  • Unable to verify if Enanta Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Enanta Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Enanta Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Enanta Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Enanta Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Enanta Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Enanta Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jay Luly
COMPENSATION $4,508,737
AGE 62
TENURE AS CEO 15.8 years
CEO Bio

Dr. Jay R. Luly, Ph.D. has been the Chief Executive Officer and President of Enanta Pharmaceuticals, Inc. since July 2003. Dr. Luly joined Enanta in July 2003. Previously he was employed at Oxford Bioscience Partners as an Entrepreneur in Residence. Before joining Oxford in March 2002, Dr. Luly served as Senior Vice President of R&D Operations and Senior Vice President of Discovery Strategy and Operations of Millennium Pharmaceuticals, following Millennium Pharmaceuticals, Inc. merger with LeukoSite, Inc., where he served as Senior Vice President of Drug Discovery and Pre-Clinical Development. Dr. Luly served as Vice President of Drug Discovery at LeukoSite, Inc. prior to joining LeukoSite, he held a number of senior drug discovery positions at Abbott Laboratories from 1983 to 1997. His Research and development efforts have resulted in several therapeutics reaching clinical development and he is an inventor on 45 issued U.S. patents and has authored over 150 scientific publications, abstracts and review articles. Dr. Luly has been a Director of Enanta Pharmaceuticals, Inc. since July 2003. He served as a Director of Artesian Therapeutics, Inc. He serves as a Trustee of Boston Biomedical Research Institute, Inc. Dr. Luly earned a B.S. with highest distinction from University of Illinois, Urbana/Champaign and a Ph.D. in synthetic organic chemistry from University of California, Berkeley.

CEO Compensation
  • Jay's compensation has been consistent with company performance over the past year.
  • Jay's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Enanta Pharmaceuticals management team in years:

10.4
Average Tenure
62.5
Average Age
  • The average tenure for the Enanta Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Jay Luly

TITLE
President
COMPENSATION
$5M
AGE
62
TENURE
15.8 yrs

Paul Mellett

TITLE
Senior VP of Finance & Administration and CFO
COMPENSATION
$1M
AGE
63
TENURE
15.6 yrs

Yat Or

TITLE
Senior VP of Research & Development and Chief Scientific Officer
COMPENSATION
$2M
AGE
66
TENURE
19.4 yrs

Nathaniel Gardiner

TITLE
Senior VP
COMPENSATION
$1M
AGE
64
TENURE
4.9 yrs

Nathalie Adda

TITLE
Senior VP & Chief Medical Officer
COMPENSATION
$2M
AGE
52
TENURE
3.8 yrs

Carol Miceli

TITLE
Director of Investor Relations

Tim Ocain

TITLE
Senior Vice President of New Product Strategy & Development
AGE
60
TENURE
5.3 yrs
Board of Directors Tenure

Average tenure and age of the Enanta Pharmaceuticals board of directors in years:

5.2
Average Tenure
61
Average Age
  • The tenure for the Enanta Pharmaceuticals board of directors is about average.
Board of Directors

Bruce L. Carter

TITLE
Non-Executive Chairman
COMPENSATION
$394K
AGE
75
TENURE
3.3 yrs

Jay Luly

TITLE
President
COMPENSATION
$5M
AGE
62
TENURE
15.8 yrs

Terry Vance

TITLE
Independent Director
COMPENSATION
$374K
AGE
60
TENURE
7.8 yrs

Stephen Buckley

TITLE
Independent Director
COMPENSATION
$372K
AGE
68
TENURE
6.6 yrs

George Golumbeski

TITLE
Independent Director
COMPENSATION
$367K
AGE
61
TENURE
5.2 yrs

Lesley Russell

TITLE
Director
COMPENSATION
$362K
AGE
57
TENURE
2.4 yrs

Kris Peterson

TITLE
Independent Director
COMPENSATION
$206K
AGE
59
TENURE
1.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Enanta Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Enanta Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

Details
Name: Enanta Pharmaceuticals, Inc.
9EP
Exchange: DB
Founded: 1995
$1,472,516,148
19,441,584
Website: http://www.enanta.com
Address: Enanta Pharmaceuticals, Inc.
500 Arsenal Street,
Watertown,
Massachusetts, 02472,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ENTA Common Stock Nasdaq Global Select US USD 21. Mar 2013
DB 9EP Common Stock Deutsche Boerse AG DE EUR 21. Mar 2013
Number of employees
Current staff
Staff numbers
113
Enanta Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 21:56
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/12
Last earnings filing: 2019/02/08
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/09/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.